M. Patekar

发表

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

C. Bodemer, K. Kingo, A. Kaszuba, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study

K. Schäkel, I. Hampele, B. Sigurgeirsson, 2021, The Journal of dermatological treatment.

Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients

B. Sigurgeirsson, R. Woessner, H. Hockey, 2020, British journal of clinical pharmacology.

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis

B. Elewski, M. Lebwohl, E. Soriano, 2020, JAMA dermatology.

Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis

Q. Guo, Ruo-yu Li, Hao Cheng, 2020, Chinese medical journal.

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

M. Lebwohl, A. Blauvelt, J. Bagel, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)

M. Lebwohl, A. Blauvelt, J. Bagel, 2018, Dermatology and Therapy.

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)

T. Luger, U. Mrowietz, R. Bissonnette, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial

I. Hampele, J. Szepietowski, B. Sigurgeirsson, 2021, Dermatologic therapy.

Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial *

K. Reich, M. Augustin, G. Bruin, 2022, The British journal of dermatology.

THU0411 Secukinumab Efficacy in Anti-TNF-Naive and Anti-TNF-IR Patients with Psoriatic Arthritis: Results of a Phase 3 Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)

S. Kandala, I. McInnes, A. Kavanaugh, 2015 .

Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis

Jian-Zhong Zhang, M. Zheng, M. Patekar, 2021, Chinese medical journal.

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

A. Gottlieb, P. Rahman, D. Heijde, 2015, The Lancet.

Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study

J. Szepietowski, K. Kingo, W. Bao, 2022, Pediatric Drugs.

A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results.

J. Szepietowski, K. Kingo, A. Reich, 2021, Journal of the American Academy of Dermatology.

Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial

I. Hampele, J. Szepietowski, B. Sigurgeirsson, 2021, Dermatologic therapy.